MBI spurs review of Nycomed patent
The U.S. Patent Office has granted a petition from Molecular Biosystems of San Diego asking for a review of an ultrasound contrast agent patent issued to Norwegian contrast developer Nycomed. MBI was granted a similar petition in July relating to
The U.S. Patent Office has granted a petition from Molecular Biosystems of San Diego asking for a review of an ultrasound contrast agent patent issued to Norwegian contrast developer Nycomed. MBI was granted a similar petition in July relating to ultrasound contrast patents received by Sonus Pharmaceutical (SCAN 8/6/97).
MBI said it filed the petition in response to Nycomed's assertion that MBI's Optison contrast agent infringes on one of its patents, U.S. patent no. 5,529,766. Nycomed filed patent infringement claims on Sept. 2 against MBI and Mallinckrodt, and in the same action sought to have its patents take priority over those of Sonus (SCAN 9/17/97).
MBI claims that it brought to the patent office's attention certain prior art references that were not included in Nycomed's patent application. MBI believes that the use of perfluorocarbon gases for ultrasound imaging is not patentable because of the prior art references.
MBI and its marketing partner Mallinckrodt also filed litigation in July in U.S. District Court for the District of Columbia, seeking to have the patents of Nycomed, Bracco, ImaRx Pharmaceutical and Du Pont Merck, and Sonus declared invalid.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
